CRL Charles River Laboratories International, Inc.
CRL Charles River Laboratories International, Inc.
Healthcare · Diagnostics & Research
Market read
Scan convergence 1 scan as of 2026-08-17 1 bull converging
POC $165.35 · VWAP $184.08 · +55.7% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
CRL Price Structure
Loading timeframes…
Peers
Every watchlist CRL belongs to, members best 30-day change first — CRL highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Against street estimates
How CRL's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about CRL from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 42 days ago · Jul 7
- Charles River Laboratories International (CRL) Earnings Report: Key Numbers & Transcript Summary
- CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
- CRL Q1 2026 Earnings Call Transcript
- Charles River Laboratories International, Inc. (CRL) Stock ...
- CRL News Today | Why did Charles River Laboratories International stock go down today?
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
CRL research tape
13 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to CRL.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries